Newsmeme!
Discover News you didn't know existed

• home
• news
• tagging
• how it works
• about
• data

Larynx

News

Merck Serono: European Commission Approves Erbitux For 1st-Line Use In Head And Neck Cancer

Published December 1, 2008, 6:12 am, Medical News Today

Merck Serono, a division of Merck KGaA, announced today that it has received approval from the European Commission to extend the use of its targeted therapy Erbitux® (cetuximab) to include 1st-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Full Story

Tags

No tags found at this time. Be the first to tag this news item, learn more.

Imagery

Related Larynx Stories

From Various News Sources

Merck Serono: European Commission Approves Erbitux for 1st-Line Use in ... - PharmiWeb
Erbitux approved for 1st-line use in combination with platinum-based chemotherapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck in Europe Approval based on the results of the EXTREME study, which showed ...

European Commission Approves Erbitux for First-Line Use in Head and ... - Phramalive.com
Approval based on the results of the EXTREME study, which showed first significant overall survival benefit in this setting in 30 years DARMSTADT, Germany, December 1, 2008 ? Merck KGaA and its Merck Serono division announced today that it has ...

Related Social Bookmarks

None found at this time.